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Biological agents or ‘‘biologics” are widely used in oncology practice for cancer treatment and for the sup-
portive management of treatment-related side effects. Unlike small-molecule generic drugs, exact copies
of biologics are impossible to produce because these are large and highly complex molecules produced in
living cells. The term ‘‘biosimilar” refers to a biological product that is highly similar to a licensed biolog-
ical product (reference or originator product) with no clinically meaningful differences in terms of safety,
purity, or potency. Biosimilars have the potential to provide savings to healthcare systems and to make
important biological therapies widely accessible to a global population. As biosimilars for rituximab, tras-
tuzumab, and bevacizumab are expected to reach the market in the near future, clinicians will soon be
faced with decisions to consider biosimilars as alternatives to existing reference products. The aim of this
article is to inform oncology practitioners about the biosimilar development and evaluation process, and
to offer guidance on how to evaluate biosimilar data in order to make informed decisions when integrat-
ing these drugs into oncology practice. We will also review several biosimilars that are currently in devel-
opment for cancer treatment.
 2016 Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).Introduction
New agents for the treatment and supportive care of cancer
have markedly improved therapeutic options and outcome for
many malignancies. Biologics include monoclonal antibodies
(mAbs) targeted to critical pathways involved in cancer pathogen-
esis and growth factors to reduce or ameliorate treatment-related
hematological toxicity. Unfortunately, access to potentially life-
saving biologics is limited in many areas of the world [1–3]. As
the patent expiry of several drugs approaches, there has been
intense interest in developing biosimilar agents to introduce cost
savings for healthcare systems and to widen global access to key
biological therapies [1,2,4].
A biosimilar drug is a biological product that is highly similar,
but not identical, to a licensed biological product (the reference
or originator product) [5–7]. Unlike small-molecule generic drugsthat are typically chemically synthesized and easy to replicate, it
is impossible to make exact copies of reference products because
biosimilars (as biologics) are large and highly complex molecules
produced in living cells. Structural differences to the reference pro-
duct may arise due to variations in post-translational modification
(such as glycosylation patterns), which could have impact upon
drug efficacy or safety [5–7]. The development of biosimilars there-
fore involves extensive evaluation and a detailed, comprehensive
manufacturing process to ensure that there are no clinically mean-
ingful differences in purity, safety, or potency [5–7]. As is the case
for any new therapeutic agent, the evaluation process and approval
requirements for a proposed biosimilar may differ between regula-
tory agencies, leading to differential access based on geographic
location.
Drugs for supportive care were the first biosimilars to gain
approval for use, with the European Union (EU) approval in 2007
of epoetin alfa and filgrastim [8]. The first biosimilar approved in
the United States (US) was filgrastim in 2015 [9]. Patents for sev-
eral biologic mAbs for cancer treatment have recently expired in
the EU and will soon expire in the US (see Table 1 for products
and patent expiration dates). This has instigated multiple biosimi-
lar development programs and regulatory approval requests for
newly developed biosimilar agents. Biosimilars for rituximab,
Table 1
Biosimilar mAbs with registered phase III clinical trials for oncology.a
Reference product Patent
expiration
in EU/US
Biosimilar Manufacturer Primary
endpoint
Condition Published datab
Trastuzumab (Herceptin,
Genentech)
2014/2019 BCD-022 Biocad ORR HER2+
MBC
Phase I: BCD-022 showed similar PK and safety to trastuzumab in
patients with HER2+ MBC [33]
PF-
05280014
Pfizer PK, pCR
(2nd)
HER2+
EBC
Preclinical: PF-05280014 showed similar structural and functional
properties, PK and immunogenicity profiles to trastuzumab [34]
ORR HER2+
MBC
Phase I: PF-05280014 showed similar PK, safety and immunogenicity
to trastuzumab in healthy volunteers [35]
ABP 980 Amgen ORR HER2+
EBC
Phase I: ABP 980 showed comparable PK, PD, safety, tolerability and
immunogenicity to trastuzumab in healthy volunteers [36]
CT-P6 Celltrion pCR HER2+
EBC
Phase I/IIB: CT-P6 showed equivalent PK and similar safety to
trastuzumab in patients with HER2+ MBC [37]
pCR HER2+
MBC
Phase III: CT-P6 showed similar efficacy (ORR) and safety to
trastuzumab in combination with paclitaxel [38]
SB3-G31-
BC
Samsung
Bioepis
pCR HER2+ BC No published data
Hercules/
Myl1401O
Mylan GmbH ORR HER2+
MBC
No published data
Rituximab (Rituxan,
Genentech/Biogen Idec;
MabThera, Roche)
2013/2016 GP2013 Sandoz ORR FL Preclinical: GP2013 showed physicochemical and functional
characteristics comparable to rituximab [39]
Preclinical: GP2013 showed similar in vitro potency and similar PK,
PD, and efficacy to rituximab [40]
BCD-020 Biocad CD20+
count
ORR
Indolent
NHL
Phase III: BCD-020 showed equivalent PK and similar PD and safety to
rituximab in patients with indolent NHL [41]
Phase III: BCD-020 showed similar efficacy (ORR) and safety to
rituximab in patients with indolent B-cell non-Hodgkin’s lymphoma
[42]
PF-
05280586
Pfizer ORR LTBFL Preclinical: PF-05280586 showed similar structural and in vitro
functional characteristics and similar in vivo PK and immunogenicity
profiles to rituximab [43]
Phase I: PF-05280586 showed similar PK, effectiveness, and safety to
rituximab in subjects with active rheumatoid arthritis [44]
CT-P10 Celtrion ORR FL Phase III: CT-P10 showed equivalent PK and similar efficacy (ACR20/
50/70), PD, safety [45], and immunogenicity [46] to rituximab in
subjects with rheumatoid arthritis
RTXM83 mAbxience ORR DLBCL Preclinical: RTXM83 showed similar structural and in vitro functional
characteristics and similar in vivo PK/PD profiles to rituximab [47]
Phase III: RTXM83 showed comparable PK and safety profile
(immunogenicity) to rituximab when combined with CHOP for first-
line treatment of DLBCL [48]
ABP 798 Amgen RD, ORR NHL No published data
Bevacizumab (Avastin

,
Genentech)
2022/2019 BCD-021 Biocad ORR NSCLC Phase I: BCD-021 showed similar PK and safety to bevacizumab in
patients with NSCLC [49]
Phase III: BCD-021 showed similar efficacy (ORR), safety and
immunogenicity to bevacizumab in patients with advanced non-
squamous NSCLC [50]
PF-
06439535
Pfizer ORR NSCLC Preclinical: PF-06439535 showed similar structure and in vitro
biological activity [51] and similar in vivo toxicologic and toxicoki-
netic to bevacizumab [52–54]
Phase I: PF-06439535 demonstrated PK similarity and comparable
safety profiles to bevacizumab [53]
ABP 215 Amgen ORR NSCLC Preclinical and Phase I: ABP 215 showed similar in vitro functional
characteristics and equivalent human PK to bevacizumab
DLBCL, diffuse large B-cell lymphoma; EBC, early breast cancer; FL, follicular lymphoma; HER2+, human epidermal growth factor receptor 2–positive; LTBFL, low tumor
burden follicular lymphoma; MBC, metastatic breast cancer; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; pCR, pathological
complete response; PD, pharmacodynamics; PK, pharmacokinetics; RD, risk difference.
a Registered on ClinicalsTrials.gov, the International Clinical Trials Registry Platform, or the European Union Clinical Trials Register.
b Published on PubMed, Web of Science, or congress websites.
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the near future, and clinicians will soon be faced with decisions to
utilize biosimilars as alternatives to existing reference products.
The aim of this article is to inform oncology practitioners aboutthe biosimilar development and evaluation process, including rel-
evant clinical trial design issues, and to enable critical appraisal
of data to allow for best informed decision making when integrat-
ing biosimilars into practice.
Table 2
Studies to demonstrate structural and functional similarity between a proposed
biosimilar and trastuzumab.
Study Purpose
In vitro studies to demonstrate physicochemical similarity
Liquid chromatography/mass
spectrometry for peptide
mapping
To compare the sequence of amino acids
that constitutes the primary structure
N-linked oligosaccharide
profiling/glycan patterns
To compare glycosylation patterns
resulting from post-translational
modifications
Imaged capillary isoelectric
focusing
To detect charged isoforms heterogeneity
Size exclusion HPLC To compare the degree of purity in terms
of the levels of monomer and high
molecular mass species
In vitro studies to demonstrate functional similarity
Inhibition of tumor cell growth To demonstrate similar inhibition of
HER2-expressing cell growth
Antibody-dependent
cell-mediated cytotoxicity
To demonstrate similar ability to induce
cell death by binding to natural killer cells
HER2 binding assay To demonstrate that the biosimilar exert
its clinical activity through the same
mechanism of action as trastuzumab
Fcc RIIIa binding assay
FccRIIIa, cell surface receptor for immunoglobulin G Fc; HER2+, human epidermal
growth factor receptor 2–positive; HPLC, high-performance liquid chromatography.
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oncology
Biosimilarity is confirmed when ‘‘the biological product is
highly similar to the reference product notwithstanding minor dif-
ferences in clinically inactive components, and there are no clini-
cally meaningful differences between the biological product and
the reference product in terms of the safety, purity, and potency
of the product” [6]. The regulatory requirements for establishing
biosimilarity are science-based and generally similar for the Euro-
pean Medicines Agency (EMA), US Food and Drug Administration
(FDA), and World Health Organization (WHO) [5–7]. The approval
process for biosimilars includes extensive comparisons between
the proposed biosimilar and the reference biological agent to
assess overall similarity (Fig. 1). A stepwise process starts with
an analytical and nonclinical comparison of structural and
in vitro functional characteristics and in vivo animal studies,
including assessments of toxicity. The extent and nature of data
required at each step depends on the level of evidence obtained
in the preceding steps. The type and amount of data considered
to be sufficient to demonstrate biosimilarity is also determined
on a product-specific basis. Final approval is dependent on one or
more comparative clinical studies in an appropriate clinical setting,
with at least one study including an assessment of immunogenicity
and pharmacokinetics [PK] or pharmacodynamics [PD] demon-
strating safety, purity, and clinical efficacy of the biosimilar.Data required to demonstrate biosimilarity
The goal of the biosimilar development program is to demon-
strate high similarity to the reference product. Due to the complex-
ity of biologics and the lack of access to proprietary manufacturing
data, developers reverse engineer the reference product to create a
biological product (biosimilar) that is highly similar to it.Reverse engineering to 
create a biosimilar:
Production of a large and 
highly complex protein in 
living cells
Nonclinical in vitr
Extensive physi
and biological 
characterization
Data a
decisio
progre
Comparative clinical efficacy 
and safety studies in most 
sensitive patient population 
Regulators assess the tot
from in vitro, in vivo, and c
Regulatory a
Data are presented
Fig. 1. The biosimilar deNonclinical in vitro studies
The basis for establishing biosimilarity involves an extensive
physicochemical and biological characterization. Hence, the non-
clinical in vitro program has to include robust analytical tech-
niques along with sensitive biochemical and functional assays to
detect any potential variability between the reference product
and the biosimilar. Table 2 shows examples of studies conducted
to demonstrate structural and in vitro functional similarity of pro-
posed biosimilars to trastuzumab (Herceptin

, Genentech Inc,
South San Francisco, CA), a humanized recombinant mAb targetingo studies:
cochemical 
Nonclinical in vivo studies 
in animals:
May be needed to 
address remaining safety 
uncertainties
re presented to regulators and a 
n is made whether biosimilar can 
ss to clinical development
Comparative PK, PD, and 
immunogenicity studies
ality-of-the-evidence 
linical studies
pproval
 to regulators 
velopment process.
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receptor 2 (HER2), and approved in the US and the EU for treat-
ment of HER2+ breast and gastric cancers. Differences between a
proposed biosimilar and trastuzumab detected by any of these
analyses may affect the binding, biological activity, immunogenic-
ity or patient safety.
Nonclinical in vivo studies
The nonclinical in vivo program follows a stepwise approach
recommended by the EMA, FDA, and WHO [6,7,10]. According to
EMA guidelines, based on the outcome of the extensive structural
and functional comparisons, a decision will be made to determine
the need for in vivo studies in animals and, if so, the extent and
focus of these studies [5]. Animal studies may be needed to address
remaining uncertainties about safety and to provide additional evi-
dence before advancing to clinical studies in humans. It should be
noted that different strategies may be applied to the nonclinical
development of different biosimilars, depending on what is known
about the development program of the reference product. Based on
the totality of evidence (i.e. consideration of the quantity and qual-
ity of the evidence to support biosimilarity) from the nonclinical
program, a decision is then made about whether to continue with
the development of the biosimilar and to proceed to clinical
studies.
Clinical studies
The goal of the clinical program is not to demonstrate clinical
efficacy per se, as this was established for the reference product,
but to address any residual uncertainty about biosimilarity after
conducting physicochemical and biological characterization and,
where appropriate, animal studies [5,6]. Comparative clinical stud-
ies are conducted to demonstrate similarity between the biosimilar
and the reference product in a stepwise manner beginning with PK,
PD (if relevant markers exist), and immunogenicity studies fol-
lowed by comparative clinical efficacy and safety (including
immunogenicity) study/studies. The extent of clinical evaluations
may depend on the degree of biosimilarity shown in the nonclini-
cal phase [5,6].Biosimilar mAbs in development for cancer treatment
Many biosimilar mAbs are currently in development for the
treatment of cancer (Table 1). Specific requirements for the clinical
development of biosimilars in oncology are based on the approval
process of the reference product and are developed with regulatory
input. The EMA guidelines for biosimilar mAbs licensed for oncol-
ogy indications stipulate that the most sensitive patient population
and clinical endpoints should be used to detect differences in effi-
cacy and safety between a biosimilar and a reference product [11].
The guidelines further recommend using a homogeneous patient
population and an endpoint that measures activity, such as overall
response rate (ORR), ORR at a certain time point, or pathological
complete response (pCR) [11]. The biosimilars shown in Table 1
have completed their preclinical assessments and, based on the
totality of evidence, progressed to clinical testing. However,
oncologists should be aware that in some countries several
non-comparable copies of biological products (sometimes called
‘intended copies’) have been introduced without the proper
demonstration of biosimilarity to a licensed reference product
and without approval via a regulatory pathway aligned with
EMA, FDA, or WHO guidelines [12–14]. Biologics with unknown
quality and clinical profile may pose an increased risk to patient
safety and may not demonstrate clinical efficacy [14].Factors that may influence the integration of biosimilars into
oncology practice
Patient population for efficacy evaluation
Regulatory guidelines recommend using the most sensitive
patient population in clinical biosimilar trials so that potential
differences in efficacy, safety, and/or immunogenicity could be
attributed to the drug itself and not the patient population [11].
In the case of trastuzumab, clinical studies to demonstrate biosim-
ilarity are being conducted in settings in which trastuzumab has
demonstrated efficacy: in early breast cancer (EBC) as neoadjuvant
therapy, and as first-line treatment for metastatic breast cancer
(MBC) [15–24]. Both settings have advantages and disadvantages,
with longer treatment required in the metastatic setting, but less
data on long-term efficacy and safety in the neoadjuvant setting.
In the case of rituximab, clinical studies to demonstrate biosimilar-
ity are underway in the appropriate histologic subtypes of
non-Hodgkin’s lymphoma, including both low grade and high grade
disease. Most clinical studies designed to demonstrate biosimilarity
to bevacizumab are being conducted in patients with previously
untreated advanced non-small-cell lung cancer, a population with
a well categorized safety and efficacy profile for treatment with
bevacizumab in combination with paclitaxel and carboplatin.Efficacy endpoints
The primary endpoints of a biosimilar clinical trial will usually
be chosen to detect clinically relevant differences between the pro-
posed biosimilar and the reference product, and it is important to
note that the endpoints may be different to those used for the
approval of the reference product. Recognizing that the preferred
endpoint to prove efficacy in cancer, e.g. progression-free survival
(PFS) or overall survival, may not be feasible or sensitive enough to
demonstrate biosimilarity between a proposed biosimilar and the
reference product, the EMA recommends using a clinical endpoint
that measures activity as primary endpoint, such as ORR or pCR
[11]. Meta-analyses of trastuzumab clinical trials data suggested
that pCR in the neoadjuvant HER2+ setting is a sensitive efficacy
endpoint to establish initial similarity, as is ORR in the first-line
metastatic setting [25]. Accordingly, for trastuzumab biosimilars,
both pCR and ORR may be used as primary endpoints in clinical
comparative studies. For rituximab biosimilars, all ongoing clinical
comparative studies use ORR as a primary endpoint; however, this
is a primary endpoint that was not used in clinical trials for the ref-
erence product rituximab. ORR is also the primary endpoint in clin-
ical studies designed to demonstrate biosimilarity to bevacizumab.Extrapolation of indication
Because the clinical portion of the comparability exercise
between a biosimilar and its reference product is typically limited
to one or two phase III comparative clinical trials, some physicians
may be concerned about using the biosimilar for indications in
which it has not been studied but for which the reference product
is approved. This is referred to as extrapolating data from clinical
studies in one medical condition to support another medical con-
dition. EMA, FDA, and WHO regulatory guidelines allow extrapola-
tion of indications when there is sufficient scientific justification
and the totality of evidence demonstrates biosimilarity and known
mechanism of action [6,7,10]. Nonetheless, there are ongoing dis-
cussions regarding the best setting to demonstrate biosimilarity
of efficacy and safety that will allow indication extrapolation.
The first biosimilar mAb (marketed as Remsima and Inflectra)
approved by EMA was granted approval for all indications of the
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indicated for a variety of medical conditions (Crohn’s disease, pedi-
atric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis,
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis,
and plaque psoriasis), there was a debate about the data required
to allow indication extrapolation. However, the EMA granted
approval to all indications not only based on the two comparative
clinical studies conducted in patients with ankylosing spondylitis
and rheumatoid arthritis, but also on the similarity demonstrated
in the preclinical program (analytical and functional in vitro stud-
ies), nonclinical in vivo and clinical phase I studies, and on the
known main mechanism of action [26,27].
Rituximab has the largest market of any monoclonal antibody
agent, and clinicians have raised similar concerns about extrapo-
lating data from clinical studies of rituximab biosimilars in
rheumatoid arthritis to non-Hodgkin lymphoma (NHL), and from
one NHL clinical setting to another, including different histological
subtypes, palliative versus curative strategies, and monotherapy
versus combination (with chemotherapy) regimens. For example,
clinical studies to demonstrate biosimilarity are underway in
appropriate histological subtypes of NHL for which rituximab is
approved [25], but are investigating these agents in first-line treat-
ment of indolent NHL even though rituximab monotherapy is not
approved in the EU or the US for the first-line treatment of follicu-
lar lymphoma [26]. While the monotherapy design was deliber-
ately chosen to allow assessment of biosimilarity without the
potentially confounding issue of combining rituximab with
chemotherapy, extrapolation of indication will only be acceptable
with appropriate scientific justification and if the clinically rele-
vant mechanism of action is proved to be the same.
Trastuzumab is the standard of care for patients with HER2-
positive breast cancer and clinical benefit including improved sur-
vival has been demonstrated with the addition of trastuzumab to
chemotherapy in several clinical studies [8,23,28], and in both
early and late stage disease. Clinical studies to demonstrate
biosimilarity in the metastatic setting have used an approach in
which the biosimilar is continued as a single agent after initial
treatment including chemotherapy. Extrapolation to other combi-
nations and indications can be justified if biosimilarity is estab-
lished based on the totality of the evidence and the mechanism
of action is shown to be the same in the different indications.
Similarly, for bevacizumab, most comparative clinical studies are
conducted in the fist-line setting in advanced NSCLC, a population
that is well characterized and considered to be sensitive enough to
detect potential differences between a proposed biosimilar and
bevacizumab. Once biosimilarity is established based on the pre-
clinical and clinical data and the mechanism of action is proved
to be the same, extrapolation to other indications for bevacizumab
(i.e. metastatic colorectal cancer, metastatic renal cell cancer and
certain gynaecologic cancers) may be justified.
Post-approval safety monitoring
Immunogenicity is a key element in establishing biosimilarity
between the proposed biosimilar and the reference product and
is assessed in both nonclinical and clinical studies. However, clin-
ically meaningful immune responses to a biological agent may
develop after long-term use, with the potential to affect both the
safety and efficacy of the agent. For example, a change in the man-
ufacturing process of the originator epoetin (Eprex, Janssen) led to
increased rates of antibody-mediated pure red cell aplasia in the
EU between 1998 and 2004 [29]; this further emphasizes the
importance of post-approval monitoring for immunogenicity.
Accordingly, the clinical safety of all biological products, including
biosimilars, must be monitored on an ongoing basis during the
post-approval period of use. This will enable the identification ofrare but potentially serious safety risks (e.g. immunogenicity) not
detected during the shorter follow-up of clinical studies [6,7,10].
Manufacturers are responsible for setting up effective post-
marketing safety monitoring systems for biosimilar agents and
must report adverse reactions associated with the reference pro-
duct and its drug class [6,7,30]. Practicing physicians also have a
central role in ensuring patient safety in this setting and are
required to report any suspected adverse drug reaction and to
identify the associated causative drug, be it the biosimilar or the
reference product [31].Interchangeability and automatic substitution
Interchangeability refers to the medical practice of switching
from one biological agent (the reference product) to another (the
biosimilar) with the expectation of producing the same clinical
outcome as the reference product in any patient treated in a given
clinical setting. Automatic substitution occurs when an inter-
changeable biological product (e.g. biosimilar) is substituted for
the reference product by a pharmacist without the intervention
or knowledge of the healthcare provider who prescribed the refer-
ence product. It is important to note that biosimilarity does not
guarantee interchangeability. A recent recommendation from the
FDA states that in order to meet the standards for interchangeabil-
ity, ‘‘an applicant must provide sufficient information to demon-
strate biosimilarity, and also demonstrate that the biological
product can be expected to produce the same clinical result as
the reference product in any given patient and, if the biological
product is administered more than once to an individual, the risk
in terms of safety or diminished efficacy of alternating or switching
between the use of the biological product and the reference pro-
duct is not greater than the risk of using the reference product
without such alternation or switch” [32]. As such, the FDA may
approve interchangeability, but each state can decide whether to
allow automatic substitution [32]. The EMA does not provide guid-
ance regarding interchangeability; it is within the authority of
member countries [5].Summary and conclusions
As biosimilar mAbs begin to enter the landscape of cancer treat-
ment, it is increasingly necessary for cancer specialists to under-
stand the issues involved in biosimilar development to enable
them to make informed decisions when integrating these drugs
into their clinical practice. The goal of the biosimilar development
program is to demonstrate biosimilarity to the reference product in
nonclinical in vitro, nonclinical in vivo, and limited comparative
clinical trials rather than to prove clinical equivalence of long-
term efficacy, safety, and immunogenicity for all the approved
indications of the reference product. The regulatory framework
for the development of biosimilars is evolving on a global scale
and robust efforts are being made to manufacture high-quality,
safe, and effective biosimilar agents.
In general, oncologists will rely on the EMA/FDA review and
approvals to verify that a biosimilar is highly similar to the refer-
ence product with no clinically significant differences. However,
an understanding of key issues will help when integrating biosim-
ilars into clinical practice (Table 3), albeit that in some regions, the
health commissioners rather than clinicians will determine the
timing of the switch to a biosimilar and the indications for use.
There may be subtle differences in the chemical structure and
immunogenicity compared with the reference product, which
may alter the clinical response, long-term outcome or toxicity over
time. Therefore, a post-marketing safety monitoring system is put
Table 3
Key issues oncologists should consider when prescribing biosimilars.
 Regulatory approval information
 Interchangeability status for FDA-approved biosimilars
 Substitution practice within their country/state
 Approved indications (including via extrapolation)
 Available safety data (including immunogenicity) – physicians play a key
role in documenting any adverse drug reaction post approval.
FDA, US Food and drug administration.
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key role in documenting any adverse drug reactions.
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